SCHEMBL279455

SCHEMBL279455

CON(C)C(=O)c1c(C)c2c(N)ncnn2c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 10/20 0.43
FGFR3 P22607 6/20 0.43
PLK4 O00444 1/20 0.43
AURKA O14965 1/20 0.43
DAPK3 O43293 1/20 0.43
ROCK2 O75116 1/20 0.43
PAK4 O96013 1/20 0.43
CHEK2 O96017 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43
INSR P06213 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
CSF1R P07333 1/20 0.43
LYN P07948 1/20 0.43
IGF1R P08069 1/20 0.43
MET P08581 1/20 0.43
KIT P10721 1/20 0.43
PIM1 P11309 1/20 0.43
SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10225290 0.79 FGFR1 (0.44) FGFR1FGFR3PLK4AURKADAPK3
SCHEMBL279736 0.79 FGFR1 (0.46) FGFR1FGFR3PLK4AURKADAPK3
SCHEMBL279400 0.76 PLK4 (0.45) FGFR1FGFR3PLK4AURKADAPK3
SCHEMBL12283330 0.73 CSNK2A2 (0.43) FGFR1FGFR3NTRK1CSNK2A2CSNK2A1
SCHEMBL10118033 0.73 FGFR1 (0.57) FGFR1FGFR3PLK4AURKADAPK3
SCHEMBL10118034 0.72 FGFR1 (0.45) FGFR1FGFR3PLK4AURKADAPK3
SCHEMBL13869025 0.72 NTRK1 (0.50) FGFR1FGFR3PLK4AURKADAPK3
SCHEMBL21198893 0.71 AURKB (0.48) FGFR1AURKANTRK1LCKFYN
SCHEMBL14537224 0.71 CSNK2A2 (0.43) FGFR1FGFR3NTRK1NTRK2CSNK2A2
SCHEMBL279415 0.70 FGFR1 (0.39) FGFR1FGFR3PLK4AURKADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829185-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2014-09-09 US disclosed
US-20120165314-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS BAYER HEALTHCARE LLC (US) 2012-06-28 US disclosed
US-8133995-B2 Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis BAYER HEALTHCARE LLC (US) 2012-03-13 US disclosed
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis BAYER HEALTHCARE LLV (US) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165314-A1 SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS CDK4, FLT4, CDKL4 FGFR1 19/4885FGFR3 284/4885PLK4 29/4885
US-20090281079-A1 Substituted 4-Amino-Pyrrolotriazine Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated With Angiogenesis CDK4, FLT4, CDKL4 FGFR1 19/4885FGFR3 284/4885PLK4 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.